76 related articles for article (PubMed ID: 15723604)
1. Research progress regarding
Jia Q; Ding Q; Shao K; Dang J; Zhang F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1874-1881. PubMed ID: 38448381
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in precision medicine for individualized immunosuppression.
Fu S; Zarrinpar A
Curr Opin Organ Transplant; 2020 Aug; 25(4):420-425. PubMed ID: 32520785
[TBL] [Abstract][Full Text] [Related]
3. Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma: Comment.
Daungsupawong H; Wiwanitkit V
Asian Pac J Cancer Prev; 2024 Jun; 25(6):1861-1862. PubMed ID: 38918644
[No Abstract] [Full Text] [Related]
4. Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients.
Wang L; Liu LH; Tong WH; Wang MX; Lu SC
Genet Mol Res; 2015 Nov; 14(4):15148-57. PubMed ID: 26634478
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): therapeutic and pathophysiological implications.
Kwon D; Kim SM; Correia MA
Acta Pharm Sin B; 2020 Jan; 10(1):42-60. PubMed ID: 31993306
[TBL] [Abstract][Full Text] [Related]
6. Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame.
Kim SM; Wang Y; Nabavi N; Liu Y; Correia MA
Drug Metab Rev; 2016 Aug; 48(3):405-33. PubMed ID: 27320797
[TBL] [Abstract][Full Text] [Related]
7. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.
Monostory K; Tóth K; Kiss Á; Háfra E; Csikány N; Paulik J; Sárváry E; Kóbori L
Br J Clin Pharmacol; 2015 Dec; 80(6):1429-37. PubMed ID: 26271661
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring in pediatric renal transplantation.
Weber LT
Pediatr Nephrol; 2015 Feb; 30(2):253-65. PubMed ID: 24763544
[TBL] [Abstract][Full Text] [Related]
9. PharmGKB summary: very important pharmacogene information for CYP3A5.
Lamba J; Hebert JM; Schuetz EG; Klein TE; Altman RB
Pharmacogenet Genomics; 2012 Jul; 22(7):555-8. PubMed ID: 22407409
[No Abstract] [Full Text] [Related]
10. Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients.
Katsakiori PF; Papapetrou EP; Goumenos DS; Nikiforidis GC; Flordellis CS
Indian J Pharmacol; 2011 Jul; 43(4):385-8. PubMed ID: 21844990
[TBL] [Abstract][Full Text] [Related]
11. Explaining variability in ciclosporin exposure in adult kidney transplant recipients.
Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt H; Danhof M; de Fijter H; Guchelaar HJ
Eur J Clin Pharmacol; 2010 Jun; 66(6):579-90. PubMed ID: 20354687
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism.
Kóbori L; Kõhalmy K; Porrogi P; Sárváry E; Gerlei Z; Fazakas J; Nagy P; Járay J; Monostory K
Br J Clin Pharmacol; 2008 Mar; 65(3):428-36. PubMed ID: 18070218
[TBL] [Abstract][Full Text] [Related]
13. Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition.
Schwarz UI; Johnston PE; Bailey DG; Kim RB; Mayo G; Milstone A
Br J Clin Pharmacol; 2006 Oct; 62(4):485-91. PubMed ID: 16995870
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
Thervet E; Legendre C; Beaune P; Anglicheau D
Pharmacogenomics; 2005 Jan; 6(1):37-47. PubMed ID: 15723604
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
Anglicheau D; Legendre C; Beaune P; Thervet E
Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
[TBL] [Abstract][Full Text] [Related]
16. [Cytochrome P450 3A polymorphism and its importance in cyclosporine and tacrolimus therapy in transplanted patients].
Duricová J; Grundmann M
Ceska Slov Farm; 2007 Oct; 56(5):220-4. PubMed ID: 18064802
[TBL] [Abstract][Full Text] [Related]
17. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
Wang J
Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
[TBL] [Abstract][Full Text] [Related]
18. Practicability of pharmacogenetics in transplantation medicine.
van Gelder T; van Schaik RH; Hesselink DA
Clin Pharmacol Ther; 2014 Mar; 95(3):262-4. PubMed ID: 23995265
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
